Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

• Published in: Clinical cancer research 2021-12, Vol.27 (23), p.6333-6342
• Main Authors: Bauer, Sebastian, Heinrich, Michael C, George, Suzanne, Zalcberg, John R, Serrano, César, Gelderblom, Hans, Jones, Robin L, Attia, Steven, D'Amato, Gina, Chi, Ping, Reichardt, Peter, Meade, Julie, Su, Ying, Ruiz-Soto, Rodrigo, Blay, Jean-Yves, von Mehren, Margaret, Schöffski, Patrick
• Format: Article
• Language: English
• Subjects: Clinical Trials: Targeted Therapy; Gastrointestinal Stromal Tumors - drug therapy; Gastrointestinal Stromal Tumors - genetics; Gastrointestinal Stromal Tumors - pathology; Humans; Mutation; Naphthyridines - pharmacology; Proto-Oncogene Proteins c-kit - genetics; Receptor, Platelet-Derived Growth Factor alpha - genetics; Urea - analogs & derivatives; Urea - therapeutic use
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-21-1864

Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary mutations leads to refractory/relapsed disease. This study reports the results of an analysis from the phase III INVICTUS study (NCT03353753) characterizing the genomic heterogeneity of tumors from patients with advanced GIST and evaluating ripretinib efficacy across mutation subgroups. Tumor tissue and liquid biopsy samples that captured circulating tumor DNA were collected prior to study enrollment and sequenced using next-generation sequencing. Subgroups were determined by mutations and correlation of clinical outcomes and mutational status was assessed. Overall, 129 patients enrolled (ripretinib 150 mg once daily, = 85; placebo, = 44). The most common primary mutation subgroup detected by combined tissue and liquid biopsies were in exon 11 (ripretinib, 61.2%; placebo, 77.3%) and exon 9 (ripretinib, 18.8%; placebo, 15.9%). Patients receiving ripretinib demonstrated progression-free survival (PFS) benefit versus placebo regardless of mutation status (HR 0.16) and in all assessed subgroups in Kaplan-Meier PFS analysis (exon 11, < 0.0001; exon 9, = 0.0023; exon 13, < 0.0001; exon 17, < 0.0001). Among patients with wild-type by tumor tissue, PFS ranged from 2 to 23 months for ripretinib versus 0.9 to 10.1 months for placebo. Ripretinib provided clinically meaningful activity across mutation subgroups in patients with advanced GIST, demonstrating that ripretinib inhibits a broad range of mutations in patients with advanced GIST who were previously treated with three or more TKIs.